GLP-1 Medications: What They Do, and What They Don't

GLP-1 agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are the most significant pharmacologic advance in metabolic medicine in a generation. They're powerful, but they're not magic, and they're not for everyone.

Mechanically, they mimic a hormone your gut already releases after meals. They slow gastric emptying, blunt appetite, and improve insulin sensitivity. The result for most patients is dramatically reduced hunger and a 15–22% reduction in body weight over 12–18 months.

Where things go wrong is when these medications are prescribed in isolation — a monthly script, no labs, no nutrition plan, no strength training. Patients lose weight, but a meaningful fraction of that loss is muscle.

In our practice, we treat GLP-1s as one tool inside a comprehensive plan. The plan, not the drug, is what produces lasting results.